Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Ahren Innovation Capital LLP. (4/2/18). "Press Release: Ahren Leads $30MN Funding Round in Cambridge Epigenetix".

Organisations Organisation Ahren Innovation Capital LLP
  Organisation 2 Cambridge Epigenetix Ltd. (CEGX)
Products Product epigenetics / epigenomics
  Product 2 venture capital
Index terms Index term Cambridge Epigenetix–SEVERAL: investment, 201804 financing round Series C $30m led by Ahren Innovation Capital
  Index term 2 Cambridge Epigenetix–Ahren Innovation Capital: investment, 201804 financing round Series C totalling $30m incl lead investor Ahren Innovation Capital
Persons Person Mellad, Jason (Start Codon 201904– CEO before Cambridge Epigenetix CEO)
  Person 2 Newcombe-Ellis, Alice (Ahren Innovation Capital 201902 Managing Partner + Founder)
     


Ahren has led the successful $30MN Series C funding round for Cambridge Epigenetix (“CEGX”) with strong participation from existing investors. CEGX is a pioneer in the development and application of epigenetic technologies and aims to change the way medicine is practiced by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification.

CEGX’s proprietary discovery platform enables the affordable and accurate identification of disease specific hydroxymethylated (5hmC) DNA from blood and tissue samples — enhancing human health through more accurate and earlier diagnosis of cancer, improved patient stratification and the development of liquid biopsy-based tests.

CEGX, spun out of the University of Cambridge in 2012 and co-founded by Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao, is at the forefront of the revolutionary field of epigenetics and has attracted investment from world leading investors including Ahren, Sequoia, GV, New Sciences Ventures and Syncona.

Jason Mellad, PhD, CEO at CEGX, said; “This funding will give us the potential to transform patient care. As a person’s epigenetic code changes over time, testing could become routine and regular. Ahren is a great partner for CEGX, sharing our vision and values, and I know they will contribute to our long-term success.”

Alice Newcombe-Ellis, Founder & CEO, Ahren Innovation Capital, LLP added; “CEGX is founded on deep scientific research. They are at the cutting edge of this science and bring a seasoned team with a fantastic track record. It is an exciting moment for the company, in a large and vital market. This is just the beginning and we share the vision of the Founders and current management of using deep science and deep data to keep pushing scientific boundaries.”


About Ahren LP

Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued in excess of $100BN combined.

A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology pioneers.

With a philosophy espousing the importance of relationships and trust, Ahren provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable.

For more information, contact info@ahren.co.uk or visit www.ahreninnovationcapital.com


Disclaimer:

This press release does not constitute an offer of interests in any Ahren fund. Any offer of an Ahren fund will be made through separate offering documents and in accordance with applicable laws and regulations. This press release may contain forward looking statements. These statements include, but are not limited to, discussions related to Ahren's expectations regarding the performance of its business, its liquidity and capital resources and the other statements contained herein. These forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. When used in this press release, the words “believe,” “anticipate,” “estimate,” “expect,” “intend” and similar expressions are intended to identify forward-looking statements. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. These statements are subject to certain risks, uncertainties and assumptions. Ahren gives no undertaking or assumes any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Ahren believes that selected case studies should be considered as a reflection of Ahren’s investment process, and references to these particular portfolio companies should not be considered as recommendations of any particular security, investment or portfolio company. The information provided about these portfolio companies is intended to be illustrative, and is not intended to be used as an indication of the current or future performance of the portfolio companies of the fund that Ahren manages.

   
Record changed: 2019-07-13

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Ahren Innovation Capital LLP


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top